| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.84 M USD | -50.47 M USD | -52.48 M USD | -48.75 M USD | -31.96 M USD | 34.26 M USD | -29.42 M USD | -21.30 M USD | 3.49 M USD | -17.86 M USD | -28.07 M USD | -19.45 M USD |
| Depreciation & Amortization | 368000 USD | 383000 USD | 386000 USD | 326000 USD | 285000 USD | 109000 USD | 80000 USD | 53000 USD | 85000 USD | 58000 USD | 64000 USD | 50000 USD |
| Stock-Based Compensation | -144000 USD | 2.28 M USD | 3.59 M USD | 8.35 M USD | 10.24 M USD | 6.80 M USD | 6.56 M USD | 3.22 M USD | 2.30 M USD | 2.72 M USD | 4.22 M USD | 4.75 M USD |
| Capital Expenditures | 0 USD | 7000 USD | 35000 USD | 479000 USD | 708000 USD | 894000 USD | 217000 USD | — | 51000 USD | 4000 USD | 15000 USD | 50000 USD |
| Cash Flow from Investing | 35.15 M USD | 49.14 M USD | 53.69 M USD | 6.89 M USD | 24.71 M USD | -106.29 M USD | 24.32 M USD | -44.33 M USD | -10.08 M USD | 9.97 M USD | -10.06 M USD | -35.07 M USD |
| Cash Flow from Financing | 0 USD | -11.87 M USD | -40000 USD | 49.05 M USD | 3.47 M USD | 74.78 M USD | 1.39 M USD | 70.48 M USD | 4.21 M USD | — | 43.07 M USD | 32.72 M USD |
| Dividends Paid | 0 USD | 11.66 M USD | 0 USD | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -20.84 M USD | -50.48 M USD | -52.52 M USD | -49.23 M USD | -32.67 M USD | 33.36 M USD | -29.64 M USD | — | 3.44 M USD | -17.86 M USD | -28.08 M USD | -19.50 M USD |
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.